Phase 2, randomized, open label, multicenter study of intradermal IMA901 plus GM-CSF [granulocyte macrophage-colony stimulating factor] with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease.

Trial Profile

Phase 2, randomized, open label, multicenter study of intradermal IMA901 plus GM-CSF [granulocyte macrophage-colony stimulating factor] with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2014

At a glance

  • Drugs IMA 901 (Primary) ; Cyclophosphamide; Granulocyte-macrophage colony-stimulating factors
  • Indications Renal cancer; Renal cell carcinoma
  • Focus Therapeutic Use
  • Sponsors immatics biotechnologies GmbH
  • Most Recent Events

    • 03 Jul 2013 New source identified and integrated (German Clinical Trials Register, DRKS00004034).
    • 28 Mar 2012 Planned patient number is 20 according to European Clinical Trials Database (Extension trial: EudraCT2008-000213-30).
    • 28 Mar 2012 Planned patient number is 20 according to European Clinical Trials Database (Extension trial: EudraCT2008-000213-30).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top